NEW YORK – Diagnostics developer Scope Fluidics has secured €6.2 million in new funding to advance its molecular diagnostic system, PCR One, it said on Monday.
Specifically, Scope Fluidics has raised €4.5 million ($5.3 million) from the sale of 127,915 offered shares, and obtained €1.7 million from the National Centre for Research and Development in Poland for its subsidiary Curiosity Diagnostics, which is developing the PCR One system.